Last updated on October 2018

Safety and Efficacy Study of Fluticasone Furoate/Vilanterol (FF/VI) Fixed Dose Combination (FDC) Compared to FF Alone in Subjects With Asthma


Brief description of study

The goal of asthma treatment is to achieve and maintain asthma control and to reduce the future risk of exacerbations. Inhaled corticosteroids (ICS) are considered as the most effective anti- inflammatory treatment for all severities of persistent asthma. For children >=5 years of age and adolescents whose asthma is uncontrolled, low-dose ICS plus adjunctive therapy with long-acting beta agonist (LABA) is considered as effective. Thus, this study is designed to evaluate the efficacy and safety of FF (ICS component)/VI (LABA component) compared to FF alone for the treatment of asthma, in subjects aged 5 to 17 years old currently uncontrolled on ICS. The study will be conducted over a total duration of approximately 29 weeks: 4 week run-in period, 24-week double-blind treatment period and 1-week follow-up period. Subjects will be randomized to receive FDC of FF/VI or FF administered via ELLIPTA dry powder inhaler (DPI). The dose of both FF/VI and FF alone will be selected based on the age of subjects. Subjects will receive a short acting beta 2 agonist (SABA) (albuterol /salbutamol) as a rescue medication throughout the study. A total of 870 subjects will be randomized in the study. Of this, 652 subjects will be aged 5 to 11 years (cohort A), and 218 will be aged 12 to 17 years inclusive (cohort B). ELLIPTA is a registered trademark of GlaxoSmithKline (GSK) group of companies.

Clinical Study Identifier: NCT03248128

Find a site near you

Start Over

GSK Investigational Site

Miami, FL United States
  Connect »

GSK Investigational Site

Baltimore, MD United States
  Connect »

GSK Investigational Site

Ypsilanti, MI United States
  Connect »

GSK Investigational Site

Piscataway, NJ United States
  Connect »

GSK Investigational Site

Raleigh, NC United States
  Connect »

GSK Investigational Site

Grove City, OH United States
  Connect »

GSK Investigational Site

Medford, OR United States
  Connect »

GSK Investigational Site

Orangeburg, SC United States
  Connect »

GSK Investigational Site

Houston, TX United States
  Connect »

GSK Investigational Site

San Antonio, TX United States
  Connect »

GSK Investigational Site

Little Rock, AR United States
  Connect »

GSK Investigational Site

Huntington Beach, CA United States
  Connect »

GSK Investigational Site

Riverside, CA United States
  Connect »

GSK Investigational Site

Denver, CO United States
  Connect »

GSK Investigational Site

Hialeah, FL United States
  Connect »

GSK Investigational Site

Miami Lakes, FL United States
  Connect »

GSK Investigational Site

Ocala, FL United States
  Connect »

GSK Investigational Site

Gainesville, GA United States
  Connect »

GSK Investigational Site

Evansville, IN United States
  Connect »

GSK Investigational Site

Owensboro, KY United States
  Connect »

GSK Investigational Site

Belleville, NJ United States
  Connect »

GSK Investigational Site

Edison, NJ United States
  Connect »

GSK Investigational Site

Asheville, NC United States
  Connect »

GSK Investigational Site

Charlotte, NC United States
  Connect »

GSK Investigational Site

Spartanburg, SC United States
  Connect »

GSK Investigational Site

Summerville, SC United States
  Connect »

GSK Investigational Site

Lewisville, TX United States
  Connect »

GSK Investigational Site

Palma de Mallorca, Spain
  Connect »

GSK Investigational Site

Santiago de Compostela, Spain
  Connect »

GSK Investigational Site

Hoover, AL United States
  Connect »

GSK Investigational Site

Homestead, FL United States
  Connect »

GSK Investigational Site

Des Moines, IA United States
  Connect »

GSK Investigational Site

Brick, NJ United States
  Connect »

GSK Investigational Site

Madison, WI United States
  Connect »

GSK Investigational Site

Saint Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Johannesburg, South Africa
  Connect »

GSK Investigational Site

Wexford, PA United States
  Connect »

GSK Investigational Site

Moscow, Russian Federation
  Connect »

GSK Investigational Site

Saint-Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Samara, Russian Federation
  Connect »

GSK Investigational Site

St'Petersburg, Russian Federation
  Connect »

GSK Investigational Site

Middelburg, South Africa
  Connect »

GSK Investigational Site

Bellville, South Africa
  Connect »

GSK Investigational Site

Cape Town, South Africa
  Connect »

GSK Investigational Site

Strzelce Opolskie, Poland
  Connect »

GSK Investigational Site

Saransk, Russian Federation
  Connect »

GSK Investigational Site

Tomsk, Russian Federation
  Connect »

GSK Investigational Site

Krugersdorp, South Africa
  Connect »

GSK Investigational Site

Ostrow Wielkopolski, Poland
  Connect »

GSK Investigational Site

Ostrowiec Swietokrzyski, Poland
  Connect »

GSK Investigational Site

Voronezh, Russian Federation
  Connect »

GSK Investigational Site

Yaroslavl, Russian Federation
  Connect »

GSK Investigational Site

Ciudad Autonoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Buenos Aires, Argentina
  Connect »

GSK Investigational Site

Great Neck, NY United States
  Connect »

GSK Investigational Site

Evanston, IL United States
  Connect »

GSK Investigational Site

Ciudad Autónoma de Buenos Aires, Argentina
  Connect »

GSK Investigational Site

St. Petersburg, Russian Federation
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.